Glycol salicylate is a compound used in cosmetics and pharmaceuticals. It is synthesized by reacting salicylic acid with ethylene glycol. It is known for its anti-inflammatory and analgesic properties, and is used in topical creams and lotions to relieve pain and inflammation. Glycol salicylate is also used as a fragrance ingredient and as a solvent. Research on glycol salicylate focuses on its effectiveness as a topical anti-inflammatory agent, as well as its safety profile for human use. The compound is studied due to its potential benefits in treating skin conditions such as acne and eczema. '
glycol salicylate: component of Piadar; topical ointment of the above including 1% methanol in base [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-hydroxyethyl salicylate : A benzoate ester obtained by the formal condensation of carboxy group of salicylic acid with one of the hydroxy groups of ethylene glycol [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6880 |
| CHEMBL ID | 173562 |
| CHEBI ID | 86541 |
| SCHEMBL ID | 15402 |
| MeSH ID | M0075189 |
| Synonym |
|---|
| ethylene glycol monosalicylate |
| espirosal |
| .beta.-hydroxyethyl salicylate |
| ethylene glycol salicylate |
| salicylic acid, 2-hydroxyethyl ester |
| glysal |
| nsc-72097 |
| rheumacyl |
| nsc72097 |
| gl 7 |
| glycol monosalicylate |
| 2-hydroxyethyl salicylate |
| 87-28-5 |
| spirosal |
| sarocol |
| glycol salicylate |
| ethylene glycol, monosalicylate |
| monoglycol salicylate |
| 1,2-ethylene glycol monosalicylate |
| ethylene glycol, salicylate |
| NCGC00159379-02 |
| D01557 |
| norgesic (tn) |
| glycol salicylate (jan) |
| phlogont (tn) |
| 2-hydroxyethyl 2-hydroxybenzoate |
| inchi=1/c9h10o4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11h,5-6h2 |
| lvylcbnxhhhpsb-uhfffaoysa- |
| aethylenglykolsalicylat |
| ethylenglycol-monosalicylsaeureester |
| 2-hydroxybenzoic acid, 2-hydroxyethyl ester |
| benzoic acid, 2-hydroxy-, 2-hydroxyethyl ester |
| traumasenex |
| salicylic acid, 2-hydroxyethyl ester (8ci) |
| glykolsalicylat |
| kytta-gel |
| BMSE000750 |
| phlogont |
| chebi:86541 , |
| CHEMBL173562 |
| E0113 |
| salicylic acid 2-hydroxyethyl ester |
| A842078 |
| NCGC00159379-03 |
| dtxcid4028913 |
| cas-87-28-5 |
| dtxsid4048987 , |
| tox21_113462 |
| AKOS009075810 |
| einecs 201-737-2 |
| nsc 72097 |
| unii-3i1vbb7axh |
| 3i1vbb7axh , |
| ai3-05033 |
| FT-0626298 |
| glycol salicylate [inci] |
| hydroxyethyl salicylate |
| glycol salicylate [mi] |
| hydroxyethyl salicylate [ep monograph] |
| glycol salicylate [jan] |
| glycol salicylate [mart.] |
| glycol salicylate [who-dd] |
| SCHEMBL15402 |
| NCGC00159379-04 |
| W-104034 |
| 2-hydroxybenzoic acid 2-hydroxyethyl ester |
| LVYLCBNXHHHPSB-UHFFFAOYSA-N |
| CS-B1707 |
| 2-hydroxyethyl 2-oxidanylbenzoate |
| mfcd00002862 |
| sr-01000944719 |
| SR-01000944719-1 |
| ethylene glycol monosalicylate, >=98.0% (gc) |
| hydroxyethyl salicylate, european pharmacopoeia (ep) reference standard |
| DB11323 |
| HY-B2208 |
| Q117422 |
| SY032913 |
| 2-hydroxyethyl-salicylate |
| E78954 |
| EN300-22340 |
| 2-hydroxy-benzoicacid2-hydroxyethyl ester |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| salicylates | Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 5.3538 | 0.0002 | 21.2231 | 8,912.5098 | AID743036 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 16.9301 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID91568 | Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by strand transfer method at 100 micro g/mL (experiment 1) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Discovery of HIV-1 integrase inhibitors by pharmacophore searching. |
| AID91565 | Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by 3''-processing method at 100 micro g/mL (experiment 2) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Discovery of HIV-1 integrase inhibitors by pharmacophore searching. |
| AID91564 | Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by 3''-processing method at 100 micro g/mL (experiment 1) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Discovery of HIV-1 integrase inhibitors by pharmacophore searching. |
| AID91569 | Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by strand transfer method at 100 micro g/mL (experiment 2) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Discovery of HIV-1 integrase inhibitors by pharmacophore searching. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.94) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (15.38%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (23.08%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (61.54%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||